Perspective Therapeutics shares fell 29% to $3.19 after presenting Phase 1/2a trial data for VMT-alpha-NET. Analysts split on outlook despite favorable safety profile and $174M cash position through late 2026.
Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.
Raymond James initiates MeiraGTx with Strong Buy rating and $29 price target, highlighting company's manufacturing platform and two major commercial opportunities in xerostomia and Parkinson's disease.
William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.
JPMorgan raises RAPT stock rating to Overweight with $55 target after Phase 2 trial success. Stock jumps 17% on positive chronic urticaria treatment data.
Baird raises Alto Neuroscience price target to $16 as company secures $50M funding and FDA approval to fast-track ALTO-207 depression drug development.
